Although the overall risk of venous thromboembolism (VTE) is high in patients with non-small cell lung cancer (NSCLC), risk identification is limited. The goal of this study was to estimate the incidence, risk factors and prognostic implications of VTE, and to evaluate a genetic link between oncogenes and the risk of VTE in Asian patients with NSCLC. A total of 1,998 consecutive patients with N...

BACKGROUND Venous thromboembolism (VTE) is associated with cancer. Cancer patient with thromboembolism have poorer prognosis. This study assessed the risk and mortality in pancreatic cancer patients who develop VTE. PATIENTS AND METHODS A retrospective chart review was performed of 201 patients with pancreatic cancer. RESULTS VTE was observed in 58 (28.9%) patients, 37/58 had deep vein thro...

BACKGROUND Venous thromboembolism (VTE) is a common complication in glioblastoma (GB) patients. PATIENTS AND METHODS A retrospective medical record review identified 294 GB patients with VTE or ICH; 146 patients with sufficient treatment records were included. Treatment approaches for GB patients who developed VTE were also reported. RESULTS Of 146 patients, 41 (28%) developed VTE and 3 (2%...

BACKGROUND Venous thromboembolism (VTE) prophylaxis is effective in the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in medical patients. METHODS A retrospective chart review was performed on medical inpatients at two academic hospitals in Hamilton, Ontario to investigate if patients received VTE prophylaxis as per current guidelines. RESULTS An analysis was performe...

Venous thromboembolism (VTE) occurs in about 5 percent of patients undergoing major abdominal surgeries. Prophylaxis of VTE is recommended using unfractionated heparin (UF) or low molecular weight heparin (LMWH) in high-risk patients. In spite of advantages and confirmed cost-effectiveness of LMWH, high costs of enoxaparin branded preparations limit its use. We aimed to compare the efficacy and...

Venous thromboembolism (VTE) occurs more frequently in older people. For those nursing older people in a variety of settings, knowledge of VTE prevention, diagnosis and treatment is essential. This article discusses simple, practical measures that can be used to reduce the risk of VTE, including good hydration and promotion of mobilisation. It also discusses how a VTE forms, the signs and sympt...

BACKGROUND There has been great interest in optimizing prophylaxis against venous thromboembolism (VTE) in the hospital setting. However, data from earlier studies suggest that most VTEs occur in the outpatient setting. The purposes of this observational study were to describe the frequency of VTEs occurring in the outpatient setting, characterize the prevalence of previously identified risk fa...

Familial clustering of venous thromboembolism (VTE) was described as far back as 1905 by Briggs. Although Egeberg discovered inherited deficiency of antithrombin in 1965, it was not until Dahlbäck discovered resistance to activated protein C in 1993 that it became clear that genetic factors are common risk factors of VTE. Several genes have been linked to familial aggregation of VTE and genome-...

Venous thromboembolism (VTE) i.e. deep-vein thrombosis (DVT) and pulmonary embolism (PE) is a multicausal disease that shares several risk factors with arterial thrombosis such as age, obesity, and smoking (1-6). It is well established that low to moderate alcohol intake is associated with a lower risk of arterial thrombosis (7), but data on its association with VTE are limited and the results ...

BACKGROUND Hospital-acquired (HA) venous thromboembolism (VTE) is a common source of morbidity/mortality. Prophylactic measures are underutilized. Available risk assessment models/protocols are not prospectively validated. OBJECTIVES Improve VTE prophylaxis, reduce HA VTE, and prospectively validate a VTE risk-assessment model. DESIGN Observational design. SETTING Academic medical center....